RU2246490C9 - Замещенные амиды фенилциклогексанкарбоновой кислоты, промежуточные соединения и лекарственное средство на их основе - Google Patents

Замещенные амиды фенилциклогексанкарбоновой кислоты, промежуточные соединения и лекарственное средство на их основе Download PDF

Info

Publication number
RU2246490C9
RU2246490C9 RU2001135715/04A RU2001135715A RU2246490C9 RU 2246490 C9 RU2246490 C9 RU 2246490C9 RU 2001135715/04 A RU2001135715/04 A RU 2001135715/04A RU 2001135715 A RU2001135715 A RU 2001135715A RU 2246490 C9 RU2246490 C9 RU 2246490C9
Authority
RU
Russia
Prior art keywords
carbon atoms
formula
residue
alkyl containing
compounds
Prior art date
Application number
RU2001135715/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2246490C2 (ru
RU2001135715A (ru
Inventor
Вольф-Дитрих ФРОЙНД (DE)
Вольф-Дитрих ФРОЙНД
Штефен ЛЕНСКИ (DE)
Штефен ЛЕНСКИ
Штефан Николас МЮЛЛЕР (DE)
Штефан Николас МЮЛЛЕР
Хольгер ПАУЛЬСЕН (DE)
Хольгер Паульсен
Йорг КЕЛЬДЕНИХ (DE)
Йорг Кельдених
Эрвин ХОРВАТ (DE)
Эрвин ХОРВАТ
Йоахим ШУМАХЕР (DE)
Йоахим Шумахер
Original Assignee
Байер Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Акциенгезельшафт filed Critical Байер Акциенгезельшафт
Publication of RU2001135715A publication Critical patent/RU2001135715A/ru
Publication of RU2246490C2 publication Critical patent/RU2246490C2/ru
Application granted granted Critical
Publication of RU2246490C9 publication Critical patent/RU2246490C9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2001135715/04A 1999-05-29 2000-05-16 Замещенные амиды фенилциклогексанкарбоновой кислоты, промежуточные соединения и лекарственное средство на их основе RU2246490C9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19924818A DE19924818A1 (de) 1999-05-29 1999-05-29 Substituierte Phenylcyclohexancarbonsäureamide
DE19924818.4 1999-05-29

Publications (3)

Publication Number Publication Date
RU2001135715A RU2001135715A (ru) 2003-08-20
RU2246490C2 RU2246490C2 (ru) 2005-02-20
RU2246490C9 true RU2246490C9 (ru) 2005-09-20

Family

ID=7909712

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001135715/04A RU2246490C9 (ru) 1999-05-29 2000-05-16 Замещенные амиды фенилциклогексанкарбоновой кислоты, промежуточные соединения и лекарственное средство на их основе

Country Status (36)

Country Link
US (2) US6716849B1 (zh)
EP (1) EP1185516B1 (zh)
JP (1) JP2003500475A (zh)
KR (1) KR20020003397A (zh)
CN (1) CN1200932C (zh)
AR (1) AR024100A1 (zh)
AT (1) ATE238997T1 (zh)
AU (1) AU765752B2 (zh)
BG (1) BG106107A (zh)
BR (1) BR0011061A (zh)
CA (1) CA2375186A1 (zh)
CZ (1) CZ20014288A3 (zh)
DE (2) DE19924818A1 (zh)
DK (1) DK1185516T3 (zh)
EE (1) EE200100634A (zh)
ES (1) ES2197870T3 (zh)
GT (1) GT200000083A (zh)
HK (1) HK1048810A1 (zh)
HN (1) HN2000000072A (zh)
HR (1) HRP20010955A2 (zh)
HU (1) HUP0201350A3 (zh)
IL (1) IL146392A0 (zh)
MA (1) MA25414A1 (zh)
MX (1) MXPA01012241A (zh)
MY (1) MY122576A (zh)
NO (1) NO20015810L (zh)
PE (1) PE20010167A1 (zh)
PL (1) PL352101A1 (zh)
PT (1) PT1185516E (zh)
RU (1) RU2246490C9 (zh)
SI (1) SI1185516T1 (zh)
SK (1) SK17052001A3 (zh)
SV (1) SV2004000087A (zh)
UA (1) UA73126C2 (zh)
WO (1) WO2000073275A1 (zh)
ZA (1) ZA200109263B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2524212C2 (ru) * 2008-06-16 2014-07-27 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения промежуточного продукта для синтеза этексилата дабигатрана

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1834090B (zh) * 2005-03-18 2011-06-29 中国科学院上海药物研究所 苯并咪唑类化合物、其制备方法以及用途
CA2874303C (en) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
SG11202105512PA (en) * 2018-11-25 2021-06-29 Tnt Medical Corp Orally active prodrug of gemcitabine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685918B1 (fr) 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
DE4221009A1 (de) 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Cyclohexanderivate
ATE174913T1 (de) 1992-07-31 1999-01-15 Bristol Myers Squibb Co Diphenyl oxazole-, thiazole- und imidazole- derivate als inhibitoren der wiederaufnahme des adenosins
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
DE4401893A1 (de) 1994-01-24 1995-07-27 Bayer Ag Substituierte Arylharnstoffe
HRP960015B1 (en) 1995-02-01 2000-12-31 Bayer Ag Substituted indole derivatives
DE19503160A1 (de) 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2524212C2 (ru) * 2008-06-16 2014-07-27 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения промежуточного продукта для синтеза этексилата дабигатрана

Also Published As

Publication number Publication date
PL352101A1 (en) 2003-07-28
EE200100634A (et) 2003-02-17
RU2246490C2 (ru) 2005-02-20
US6716849B1 (en) 2004-04-06
EP1185516A1 (de) 2002-03-13
DE19924818A1 (de) 2000-11-30
AR024100A1 (es) 2002-09-04
CN1365356A (zh) 2002-08-21
ES2197870T3 (es) 2004-01-16
ZA200109263B (en) 2003-01-29
UA73126C2 (en) 2005-06-15
BR0011061A (pt) 2002-03-05
JP2003500475A (ja) 2003-01-07
IL146392A0 (en) 2002-07-25
MA25414A1 (fr) 2002-04-01
CZ20014288A3 (cs) 2002-03-13
BG106107A (bg) 2002-05-31
NO20015810L (no) 2002-01-25
EP1185516B1 (de) 2003-05-02
MY122576A (en) 2006-04-29
HK1048810A1 (zh) 2003-04-17
DK1185516T3 (da) 2003-08-11
HUP0201350A2 (en) 2002-08-28
ATE238997T1 (de) 2003-05-15
HRP20010955A2 (en) 2003-08-31
PT1185516E (pt) 2003-09-30
SK17052001A3 (sk) 2002-06-04
SI1185516T1 (en) 2003-10-31
WO2000073275A1 (de) 2000-12-07
SV2004000087A (es) 2004-05-07
MXPA01012241A (es) 2002-08-12
AU765752B2 (en) 2003-09-25
GT200000083A (es) 2001-11-17
DE50001982D1 (de) 2003-06-05
HUP0201350A3 (en) 2003-05-28
PE20010167A1 (es) 2001-04-25
KR20020003397A (ko) 2002-01-12
HN2000000072A (es) 2001-02-02
AU4405500A (en) 2000-12-18
US20040186106A1 (en) 2004-09-23
CA2375186A1 (en) 2000-12-07
CN1200932C (zh) 2005-05-11
NO20015810D0 (no) 2001-11-28

Similar Documents

Publication Publication Date Title
US5314880A (en) Benzimidazole derivatives
JP3120075B2 (ja) 化合物
JP4842829B2 (ja) 含窒素縮合複素環化合物
EP1626964B1 (en) New benzimidazole derivatives
JP2005529954A (ja) 化学プロセス
RU2246490C9 (ru) Замещенные амиды фенилциклогексанкарбоновой кислоты, промежуточные соединения и лекарственное средство на их основе
EP3377062B1 (en) Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
AU766140B2 (en) Substituted phenylcyclohexane carboxylic acid amides and their use as adenosine uptake inhibitors
EP0562796A1 (en) Phenoxyacetic acid compounds and medical preparations containing them
JP2005502700A (ja) Ｃｃｒ−３受容体アンタゴニストｖ
JP2004508350A (ja) 置換フェニルシクロヘキサンカルボン酸アミドおよびその使用
JPWO2004101551A1 (ja) ベンズイミダゾール誘導体の結晶及びその製造方法

Legal Events

Date Code Title Description
TH4A Reissue of patent specification
MM4A The patent is invalid due to non-payment of fees

Effective date: 20060517